Edition:
United States

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

11.20USD
4:00pm EDT
Change (% chg)

$-0.36 (-3.11%)
Prev Close
$11.56
Open
$11.57
Day's High
$11.85
Day's Low
$11.19
Volume
75,787
Avg. Vol
81,914
52-wk High
$14.50
52-wk Low
$4.40

Latest Key Developments (Source: Significant Developments)

Medicinova Announces Pricing Of Underwritten Public Offering
Wednesday, 7 Feb 2018 07:11pm EST 

Feb 7 (Reuters) - Medicinova Inc ::MEDICINOVA ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 4.4 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $9.05 PER SHARE​.  Full Article

MediciNova Announces Proposed Underwritten Public Offering
Wednesday, 7 Feb 2018 04:00pm EST 

Feb 7 (Reuters) - MediciNova Inc ::MEDICINOVA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.MEDICINOVA INC - INTENDS TO USE PROCEEDS PRIMARILY TO CONTINUE TO FUND DEVELOPMENT OF ITS MN-166 (IBUDILAST), MN-001 (TIPELUKAST) PROGRAMS​, OTHERS.  Full Article

Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS
Thursday, 7 Dec 2017 06:00pm EST 

Dec 7 (Reuters) - Medicinova Inc ::MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS.MEDICINOVA INC - TRIAL ACHIEVED PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY, AND ALSO DEMONSTRATED EFFICACY TRENDS IN FAVOR OF MN-166.MEDICINOVA INC - THERE WERE 7 SERIOUS ADVERSE EVENTS (SAES) REPORTED DURING STUDY BUT NONE OF SAES WERE RELATED TO STUDY DRUG.MEDICINOVA INC - MN-166 DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE. ALL SUBJECTS IN STUDY RECEIVED 100 MG OF RILUZOLE PER DAY.MEDICINOVA INC - ALL TREATMENT-RELATED ADVERSE EVENTS (TRAES) WERE MILD TO MODERATE IN INTENSITY & NO SEVERE OR LIFE-THREATENING TRAES WERE REPORTED.  Full Article

Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)
Thursday, 26 Oct 2017 06:00am EDT 

Oct 26 (Reuters) - Medicinova Inc ::Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability.Medicinova Inc - ‍MN-166 demonstrated a statistically significant reduction in rate of progression of whole brain atrophy compared to placebo in study​.Medicinova Inc - ‍MN-166 was safe and well tolerated in study​.  Full Article

Medicinova Inc files for potential mixed ‍​shelf of up to $200 million
Friday, 22 Sep 2017 05:48pm EDT 

Sept 22 (Reuters) - Medicinova Inc :Medicinova Inc files for potential mixed ‍​shelf of up to $200 million - SEC filing.  Full Article

MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence
Tuesday, 19 Sep 2017 06:00am EDT 

Sept 19 (Reuters) - MediciNova Inc :MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence.MediciNova Inc - final results of phase 2 MN-166 study expected by Q1 of 2018.  Full Article

MediciNova to offer off-floor distribution of shares
Monday, 5 Jun 2017 02:53am EDT 

June 5 (Reuters) - MediciNova Inc :* Says it will offer an off-floor distribution of 800,000 shares on Tokyo Stock Exchange, from June 13 to June 15.* Offering price will be determined based on the closing share price of the day before the distribution.* Says the limitation for distribution is up to 10,000 shares for each customer.  Full Article

Medicinova announces positive findings on MN-166 (ibudilast) in alcohol dependence
Monday, 23 Jan 2017 06:00pm EST 

Medicinova Inc : Medicinova announces publication of positive findings on MN-166 (ibudilast) in alcohol dependence . Medicinova Inc - overall, MN-166 (ibudilast) was well tolerated .No severe adverse events and there were no study dropouts directly related to MN-166.  Full Article

Medicinova files for offering of up to 869,047 shares by selling stockholders
Tuesday, 29 Nov 2016 04:55pm EST 

Medicinova Inc : Files for offering of up to 869,047 shares of common stock by the selling stockholders . Says offering of shares of common stock issuable upon exercise of outstanding warrants .Says co will not receive any proceeds from resale of shares of common stock by selling stockholders.  Full Article

MediciNova sees loss per share for year ending Dec 31 of $0.31
Wednesday, 27 Jul 2016 07:44am EDT 

MediciNova Inc : Says expected loss per share for year ending December 31, 2016 is $0.31 .FY 2016 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-MediciNova Announces Proposed Underwritten Public Offering

* MEDICINOVA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK